ArticleVeterinary research communications2026
Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTylvalosin (acetylisovaleryltylosin), a breakthrough semi-synthetic derivative of tylosin engineered to address pharmacokinetic limitations and bacterial resistance, exhibits dual therapeutic efficacy against porcine reproductive and PRRSV-associated pneumonia and mycoplasma infections in swine. Limited research has yet to investigate pharmacokinetic profiles of tylvalosin and its metabolites. This study, therefore, aims to pioneer a robust UPLC-MS/MS method for simultaneous quantification of tylvalosin and its key bioactive metabolites, desmycosin 3-acetate and tylosin 3-acetate, in swine plasma and tissues, and to investigate the pharmacokinetic properties of different tylvalosin formulations.
resultsA robust UPLC-MS/MS method was developed and validated, showing excellent performance with good linearity, low deviation, high accuracy, minimal carry-over and matrix effects, as well as favorable stability under various conditions. Pharmacokinetic analysis following intravenous (i.v.) or intragastric administration in swine revealed that formulation I outperformed other formulations, exhibiting the highest bioavailability (F, 57.32%), the longest elimination half-life (t
conclusionsThe findings confirm the optimized therapeutic potential of tylvalosin, particularly formulation I, supported by its favorable pharmacokinetic profile and tissue distribution. This study establishes a new standard for veterinary PK-PD research and provides a PK evidence-based formulation optimization approaches to enhance treatment efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.